Tagged with R

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

Europe Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder collaboration, and the potential impact of a Europe-wide cancer plan.   As health stakeholders, we need to work across the…

Hungary Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials, or radiopharmaceuticals, to examine organ function and structure. Breakthroughs in neurocranial and prostate tumour treatment have brought nuclear medicine into…

Hungary As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations. Joining the company in 2015, Wienner took on her new position with the task of restructuring the stagnating affiliate. This…

USA In 2019, several drug companies testified to the US Senate Finance Committee on medicine price hikes with a narrative of discounts given to health insurance companies and pharmacists, but not then passed onto consumers. In a recent conversation with PharmaBoardroom, Matt Eyles, president & CEO of the Association of Healthcare…

Romania The Romanian Association of the Self-Care Industry (RASCI) was established in 2016 as the “voice” of the Romanian consumer healthcare industry. Diana Mereu, CEO of RASCI, discusses the association’s mission, the impact of Romania’s political volatility on the industry, the future impact of digitalization on the self-care market, and the…

UAE Growing incidence of lifestyle-related diseases, coupled with high drug prices, are driving up healthcare costs at astounding rates in the Middle East and North Africa, with experts urging preventative measures to reverse the trend.   Healthcare costs in the Gulf region are expected to rise at a greater rate than…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

Czech Republic Milan Černek, country manager of Mylan in the Czech Republic, provides expert insights into current trends in the Czech Republic’s generics and biosimilars markets, describes the affiliate’s strategy to continue growing and reinforces the company’s commitment to providing high-quality modern treatments.   The Czech Republic is a perfect example of…

China Biosimilars are a relatively recent development in the pharmaceutical industry, meaning market penetration is still fairly low, even in many developed markets, much less emerging markets. Prior to 2019, not a single biosimilar had been approved in China. However, a McKinsey analysis found that biosimilars could account for a growing…

Talent Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have moved on to new roles in their ever-expanding careers.    LATAM Expertise Pedro Galvis   Mexico is an interesting mix…

Brazil Brazil’s pharma market saw steady growth between 2005 and 2018. Revenues have more than tripled over those 13 years, ending 2018 with over USD 18 billion in revenues.   Made with Visme Presentation Maker   Brazil is gradually climbing the global pharma market rankings and is projected to leap ahead…